Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors
Hebei Senlang Biotechnology Inc., Ltd. is conducting a multicenter clinical trial to evaluate the safety and efficacy of CAR-T cell therapy in patients with relapsed/refractory plasma cell tumors. The trial targets a niche but critical segment of the oncology market, specifically addressing patients who have limited treatment options due to the refractory nature of their disease. The competitive landscape includes established CAR-T therapies, such as those targeting BCMA, which have shown promise in similar patient populations. Successful outcomes could position Hebei Senlang favorably within the CAR-T market, potentially leading to partnerships or acquisitions, especially given the increasing interest in innovative therapies for hematological malignancies. However, the trial's non-randomized, single-arm design may limit the robustness of comparative efficacy claims against existing therapies.
Indication: Plasma Cell Tumors
Modality: cell therapy
Target: BCMA (B-cell maturation antigen), CD19, CD22, CD79
Sponsor: Hebei Senlang Biotechnology Inc., Ltd.
Source URL: ClinicalTrials.gov
Source updated: Dec 11, 2020
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: BCMA (B-cell maturation antigen), CD19, CD22, CD79
View original source fields
Condition raw: Plasma Cell Tumors
Condition normalized: Plasma Cell Tumors
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: BCMA (B-cell maturation antigen), CD19, CD22, CD79
Target normalized: BCMA (B-cell maturation antigen), CD19, CD22, CD79